journal
MENU ▼
Read by QxMD icon Read
search

Urologic Oncology

journal
https://www.readbyqxmd.com/read/28087131/incidence-and-effect-of-variant-histology-on-oncological-outcomes-in-patients-with-bladder-cancer-treated-with-radical-cystectomy
#1
Marco Moschini, Paolo Dell'Oglio, Roberta Luciano', Giorgio Gandaglia, Francesco Soria, Agostino Mattei, Tobias Klatte, Rocco Damiano, Shahrokh F Shariat, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Renzo Colombo, Andrea Gallina
INTRODUCTION: We sought to describe incidence of histological variants after radical cystectomy (RC) due to bladder cancer (BCa). Moreover, we investigated survival outcomes accounting for this parameter. METHODS: We retrospectively evaluated data from 1,067 patients with BCa treated with RC between 1990 and 2013 at a single tertiary care referral center. All specimen were evaluated by dedicated uropathologists. Univariable and multivariable Cox regression analyses tested the effect of different histopathological variant on recurrence, cancer-specific mortality (CSM), and overall mortality (OM) after accounting for all available confounders...
January 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28065502/neoadjuvant-and-adjuvant-chemotherapy-use-in-upper-tract-urothelial-carcinoma
#2
Andrew Cohen, Kristine Kuchta, Sangtae Park
OBJECTIVE: To determine trends in neoadjuvant and adjuvant chemotherapy use for upper tract urothelial cancer and assess its effects on survival. MATERIALS AND METHODS: We identified all patients diagnosed with upper tract urothelial cancer who underwent surgical treatment in the SEER-Medicare database from 2002 to 2011. We collected and analyzed patient demographic, clinical, and pathologic characteristics. We strictly defined neoadjuvant and adjuvant chemotherapy and studied patients who met such criteria...
January 5, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28065395/serial-retrograde-instillations-of-sustained-release-formulation-of-mitomycin-c-to-the-upper-urinary-tract-of-the-yorkshire-swine-using-a-thermosensitive-polymer-safety-and-feasibility
#3
Nicholas M Donin, Dalit Strauss-Ayali, Yael Agmon-Gerstein, Nadav Malchi, Andrew T Lenis, Stuart Holden, Allan J Pantuck, Arie S Belldegrun, Karim Chamie
BACKGROUND: MitoGel is a novel drug formulation intended for the treatment of upper tract urothelial cancer with proven feasibility and safety in an animal model. OBJECTIVE: To evaluate the feasibility, safety, toxicokinetics, and histologic changes associated with serial retrograde MitoGel instillations to the upper urinary tract in a swine model. DESIGN, SETTING, AND PARTICIPANTS: Overall, 27 Yorkshire swine underwent 6 once-weekly unilateral retrograde instillations of MitoGel...
January 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28065394/characterizing-intermediate-risk-non-muscle-invasive-bladder-cancer-implications-for-the-definition-of-intermediate-risk-and-treatment-strategy
#4
Kazuhiro Matsumoto, Eiji Kikuchi, Yoshinori Yanai, Nozomi Hayakawa, Yujiro Ito, Takahiro Maeda, Hirohiko Nagata, Akira Miyajima, Mototsugu Oya
PURPOSE: Patients with intermediate-risk non-muscle-invasive bladder cancer have traditionally been defined as those not included in the low- or high-risk groups. Therefore, the intermediate-risk group consists of heterogeneous patients. MATERIALS AND METHODS: We reviewed 326 patients diagnosed with intermediate-risk tumors. We subclassified these patients into 3 groups according to their clinical courses. Group A included patients with initial and multiple low-grade tumors (N = 170)...
January 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28065393/quality-indicators-in-the-management-of-bladder-cancer-a-modified-delphi-study
#5
Satya R Khare, Armen Aprikian, Peter Black, Normand Blais, Chris Booth, Fadi Brimo, Joseph Chin, Peter Chung, Darrel Drachenberg, Libni Eapen, Adrian Fairey, Neil Fleshner, Yves Fradet, Geoffrey Gotto, Jonathan Izawa, Michael Jewett, Girish Kulkarni, Louis Lacombe, Ron Moore, Chris Morash, Scott North, Ricardo Rendon, Fred Saad, Bobby Shayegan, Robert Siemens, Alan So, Srikala S Sridhar, Samer L Traboulsi, Wassim Kassouf
BACKGROUND: Survival in patients with bladder cancer has only moderately improved over the past 2 decades. A potential reason for this is nonadherence to clinical guidelines and best practice, leading to wide variations in care. Common quality indicators (QIs) are needed to quantify adherence to best practice and provide data for benchmarking and quality improvement. OBJECTIVE: To produce an evidence- and consensus-based list of QIs for the management of bladder cancer...
January 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28041998/bacillus-calmette-guerin-strain-may-not-effect-recurrence-free-survival-when-used-intravesically-with-interferon-alpha2b-for-non-muscle-invasive-bladder-cancer
#6
Ryan L Steinberg, Nathan A Brooks, Lewis J Thomas, Sarah L Mott, Michael A O'Donnell
OBJECTIVES: Adjuvant intravesical Bacillus Calmette-Guerin (BCG) remains the standard-of-care for high-grade non-muscle-invasive bladder cancer (NMIBC). Conflicting reports exist regarding disparate outcomes among BCG strains. We sought to determine whether a difference in recurrence-free survival (RFS) existed between TICE BCG and Connaught BCG strains used with interferon (IFN) for the treatment of NMBIC. MATERIALS AND METHODS: A post hoc analysis of the phase 2 BCG/IFN study, conducted from May 1999 to February 2001...
December 29, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/28041997/specialist-visits-and-initiation-of-cancer-directed-treatment-among-a-large-cohort-of-men-diagnosed-with-prostate-cancer
#7
Eberechukwu Onukwugha, Candice Yong, Michael Naslund, Corinne Woods, C Daniel Mullins, Brian Seal, Arif Hussain
BACKGROUND: The urologist generally manages the treatment of men immediately following the diagnosis of prostate cancer (PCa). The role of other physician specialists in this setting is less clear. We investigated whether involvement of other physician specialty types immediately following diagnosis affects initiation of cancer-directed treatment. METHODS: This is a retrospective cohort study using linked cancer registry and claims data from 1999 to 2009, excluding stage I/II PCa...
December 29, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/28041996/utilizaton-of-perioperative-systemic-chemotherapy-in-upper-tract-urothelial-carcinoma
#8
Greg E Gin, Nora H Ruel, Steven V Kardos, John P Sfakianos, Edward Uchio, Clayton S Lau, Bertram E Yuh
INTRODUCTION: Evidence for the use of perioperative chemotherapy (PC) in upper tract urothelial carcinoma (UTUC) is largely derived from level I evidence for invasive urothelial carcinoma of the bladder (UCB). There has been an increase in PC for urothelial carcinoma of the bladder, as it has disseminated into clinical practice. Therefore, we sought to not only analyze trends in the utilization of PC in UTUC, but also assess factors associated with its use in a large cancer registry database...
December 29, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/28040419/a-novel-treatment-strategy-for-newly-diagnosed-high-grade-t1-bladder-cancer-gemcitabine-and-cisplatin-adjuvant-chemotherapy-a-single-institution-experience
#9
Guo-Liang Yang, Lian-Hua Zhang, Qiang Liu, Zhao-Liang Wang, Xue-Hui Duan, Yi-Ran Huang, Juan-Jie Bo
BACKGROUND: Management of high-grade T1 (formerly T1G3) bladder cancer continues to be controversial. Should patients with T1G3 bladder cancer have an immediate radical cystectomy or should they receive intravesical bacillus Calmette-Guérin-preserving bladder? Gemcitabine and cisplatin (GC) adjuvant chemotherapy may help to strike a balance between intravesical and early cystectomy. For purposes of this study, we continue to refer high-grade T1 lesion as "T1G3." OBJECTIVE: To evaluate the characteristics and the long-term outcome of GC adjuvant chemotherapy in T1G3 bladder cancer after transurethral resection of bladder tumor (TURBT)...
December 28, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27998677/clinically-localized-prostate-cancer-in-2017-a-review-of-comparative-effectiveness
#10
REVIEW
Hugh J Lavery, Matthew R Cooperberg
Introducing the topic of comparative effectiveness for prostate cancer treatments with a reminder of the disease's heterogeneity risks tautology. However, the profound variation both in this cancer's biology and its clinical course is increasingly widely recognized, while management alternatives for clinically localized prostate cancer have exploded. Available options now include active surveillance, multiple surgical approaches to prostatectomy, various forms of external-beam and interstitial radiation, and a growing list of energy ablative technologies...
December 17, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27986374/evaluating-the-effect-of-time-from-prostate-cancer-diagnosis-to-radical-prostatectomy-on-cancer-control-can-surgery-be-postponed-safely
#11
Nicola Fossati, Martina Sofia Rossi, Vito Cucchiara, Giorgio Gandaglia, Paolo Dell'Oglio, Marco Moschini, Nazareno Suardi, Federico Dehò, Francesco Montorsi, Riccardo Schiavina, Alexandre Mottrie, Alberto Briganti
OBJECTIVE: To test the prognostic role of treatment delay in patients affected by prostate cancer (PCa). MATERIALS AND METHODS: The study included 2,653 patients treated with radical prostatectomy (RP) at a single institution between 2006 and 2011. The evaluated outcomes were biochemical recurrence (BCR) and clinical recurrence (CR). Multivariable Cox regression analysis was used to test the association between time from diagnosis to RP and oncological outcomes...
December 13, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27956007/high-incidence-of-clinically-significant-concomitant-prostate-cancer-in-patients-undergoing-radical-cystectomy-for-bladder-cancer-a-10-year-single-center-experience
#12
Isabel Heidegger, Willi Oberaigner, Wolfgang Horninger, Renate Pichler
AIM: To analyze prostate cancer (PCa) incidence, clinical significance, and recurrence in 213 patients who underwent radical cystectomy (RC) for advanced bladder cancer (BC). PATIENTS AND METHODS: We conducted a 10-year retrospective analysis of a single-center database comprising the effect of PCa in RC specimens. RESULTS: In total, 113/213 male patients (53.1%) had PCa in the RC specimen. Patients׳ age, prostate-specific antigen (PSA), and also free PSA% were significant predictors for PCa...
December 9, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27956006/dynamics-of-three-dimensional-telomere-profiles-of-circulating-tumor-cells-in-patients-with-high-risk-prostate-cancer-who-are-undergoing-androgen-deprivation-and-radiation-therapies
#13
Landon Wark, Thomas Klonisch, Julius Awe, Cecile LeClerc, Brandon Dyck, Harvey Quon, Sabine Mai
INTRODUCTION: Accurate assessment and monitoring of the therapeutic efficacy of locally advanced prostate cancer remains a major clinical challenge. Contrary to prostate biopsies, circulating tumor cells (CTCs) are a cellular source repeatedly obtainable by blood sampling and could serve as a surrogate marker for treatment efficacy. In this study, we used size-based filtration to isolate and enumerate CTCs from the blood of 20 patients with high-risk (any one of cT3, Gleason 8-10, or prostate-specific antigen>20ng/ml), nonmetastatic, and treatment-naive prostate cancer before and after androgen deprivation therapy (ADT) and radiation therapy (RT)...
December 9, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27939349/an-initial-negative-round-of-targeted-biopsies-in-men-with-highly-suspicious-multiparametric-magnetic-resonance-findings-does-not-exclude-clinically-significant-prostate-cancer-preliminary-experience
#14
Daniel N Costa, Fernando U Kay, Ivan Pedrosa, Lauren Kolski, Yair Lotan, Claus G Roehrborn, Brad Hornberger, Yin Xi, Franto Francis, Neil M Rofsky
BACKGROUND: Targeted prostate biopsies are changing the landscape of prostate cancer (PCa) diagnosis with the degree of suspicion on multiparametric magnetic resonance imaging (mpMRI) being a strong predictor of targeted biopsy outcome. Data regarding the rate and potential causes of false-negative magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion-targeted biopsy in patients with highly suspicious mpMRI findings are lacking. OBJECTIVES: To determine the rate of clinically significant PCa detection in repeat targeted biopsy or surgery in patients with highly suspicious mpMRI findings and in an initial negative MRI-TRUS fusion-targeted biopsy...
December 8, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27955941/health-status-and-use-of-partial-nephrectomy-in-older-adults-with-early-stage-kidney-cancer
#15
Hung-Jui Tan, Timothy J Daskivich, Joseph D Shirk, Christopher P Filson, Mark S Litwin, Jim C Hu
INTRODUCTION: The long-term benefits of nephron-sparing surgery for kidney cancer depend on patient health. Accordingly, we examined whether receipt of partial nephrectomy varied with baseline comorbidity or functionality among older adults with stage I kidney cancer. MATERIALS AND METHODS: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 2000 to 2009, we identified patients treated with partial or radical nephrectomy for stage I kidney cancer...
December 7, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27955940/magnetic-resonance-imaging-transrectal-ultrasound-fusion-focal-cryotherapy-of-the-prostate-a-prospective-development-study
#16
Massimo Valerio, Taimur Tariq Shah, Paras Shah, Neil Mccartan, Mark Emberton, Manit Arya, Hashim Uddin Ahmed
OBJECTIVES: The use of software-based magnetic resonance-transrectal ultrasound fusion to deliver focal therapy may increase the precision of treatment. This is a prospective development study assessing the feasibility of Magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion focal cryotherapy. METHODS AND MATERIALS: Consecutive patients undergoing focal cryotherapy were included in an academic registry (December 2013-June 2014). MRI-TRUS fusion focal cryotherapy was offered to men with visible clinically significant prostate cancer (Galil SeedNet system)...
December 7, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27939815/patient-factors-associated-with-30-day-complications-after-partial-nephrectomy-a-contemporary-update
#17
Harras B Zaid, William P Parker, Christine M Lohse, John C Cheville, Stephen A Boorjian, Bradley C Leibovich, R Houston Thompson
INTRODUCTION: Patient-level factors associated with perioperative complications after partial nephrectomy (PN) have not been well described in a contemporary series. METHODS: Single-institution retrospective study evaluating patients undergoing open, laparoscopic, and robotic PN between 2001 and 2012. Univariable and multivariable logistic regression models were evaluated to assess factors associated with complications within 30 days of surgery. RESULTS: We identified 1,763 patients who underwent 1,773 PNs between 2001 and 2012...
December 6, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27932270/prognostic-value-of-lymph-node-yield-during-nephroureterectomy-for-upper-tract-urothelial-carcinoma
#18
Andrew G Winer, Emily A Vertosick, Mazyar Ghanaat, Renato B Corradi, Sigrid Carlsson, Daniel D Sjoberg, Alexander I Sankin, John P Sfakianos, Eugene K Cha, Guido Dalbagni, Jonathan A Coleman
INTRODUCTION: Lymph node dissection (LND) performed during radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) remains controversial and difficult to evaluate. The aim of this study was to investigate whether removal of more lymph nodes during RNU is safe and improves oncologic outcomes. METHODS: We evaluated 422 patients who underwent RNU with concomitant LND for upper tract urothelial carcinoma between 1976 and 2015, assessing for an association between total nodes removed, recurrence-free survival, and cancer-specific survival using Cox proportional hazards models...
December 5, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27932269/the-presence-of-carcinoma-in-situ-at-radical-cystectomy-increases-the-risk-of-urothelial-recurrence-implications-for-follow-up-schemes
#19
Marco Moschini, Shahrokh F Shariat, Mohammad Abufaraj, Francesco Soria, Tobias Klatte, Giovanni La Croce, Agostino Mattei, Rocco Damiano, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Renzo Colombo, Andrea Gallina
INTRODUCTION: To evaluate the incidence of carcinoma in situ (CIS) in patients treated with radical cystectomy (RC) due to bladder cancer and to assess its effect on recurrence and survival rates. METHODS: The study focused on 1,128 consecutive nonmetastatic patients with bladder cancer treated with RC at a single tertiary care referral center from 1994 to 2014. The Kaplan-Meier method was used to compare recurrence, cancer-specific mortality (CSM), and overall mortality-free rates in the overall population and in pT0-pT2 and pT3-pT4 patients after stratifying according to the presence of CIS...
December 5, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27914873/determinants-and-prognostic-implications-of-malignant-ascites-in-metastatic-papillary-renal-cancer
#20
Abhinav Sidana, Meet Kadakia, Julia C Friend, Louis S Krane, Daniel Su, Maria J Merino, Ramaprasad Srinivasan
OBJECTIVE: To describe the incidence of ascites in metastatic papillary renal cell cancer (pRCC), identify the factors associated with its development and evaluate its prognostic effect on the survival of these patients. METHODS: A retrospective evaluation of the medical records of patients with metastatic pRCC seen at National Cancer Institute (2000-2014) was undertaken. Logistic regression to identify predictors of the development of malignant ascites and Kaplan-Meier analysis to estimate survival was done...
November 30, 2016: Urologic Oncology
journal
journal
32958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"